Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 581 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lupus Erythematosus Clear all
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 22, 2026, 5:08 PM EDT
Not listed Phase 4 Interventional

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

NCT02270970
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Biological
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 22, 2026, 5:08 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

NCT06153095
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
IMPT-514
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

NCT00583362
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 22, 2026, 5:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
61
States / cities
Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
14
States / cities
Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • La Jolla, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

NCT00775476
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Recruiting Phase 2 Interventional

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 20 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00383513
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Jul 22, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

NCT01466725
View directory record Official record
Conditions
Discoid Lupus
Interventions
CC-930, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Irvine, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 22, 2026, 5:08 PM EDT
Recruiting Phase 4 Interventional

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

NCT06594068
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Withdrawn Phase 2 Interventional

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

NCT03866317
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Secukinumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

NCT01135459
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CEP-33457, Placebo
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Jul 22, 2026, 5:08 PM EDT
Active, not recruiting Not applicable Interventional

REACH (Restore Energy, Activity Can Help) Lupus Study

NCT06479213
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Fatigue
Interventions
REACH Peer Coaching Program, REACH Mobile Health Application
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

NCT01972568
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

NCT03933943
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Anniston, Alabama • Clearwater, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Jul 22, 2026, 5:08 PM EDT
Active, not recruiting Phase 3 Interventional

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
132
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

NCT04882878
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Nipocalimab, Standard-of-care treatment
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Los Alamitos, California • Rancho Mirage, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 5:08 PM EDT
Completed No phase listed Observational

A Non-drug Study Profiling Cutaneous Lupus

NCT01923415
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 22, 2026, 5:08 PM EDT
Not listed No phase listed Observational

Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization

NCT03142412
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Erythematosus, Systemic
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Jul 22, 2026, 5:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 22, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

NCT01085084
View directory record Official record
Conditions
Lupus Arthritis
Interventions
Laquinimod, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Jul 22, 2026, 5:08 PM EDT